Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire

LC–MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: Application to a clinical pharmacokinetic study

(2018) Yashpal S. Chhonker et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature

(2018) Philip J. Budge et al.   PLoS Neglected Tropical Diseases

A Trial of a Triple-Drug Treatment for Lymphatic Filariasis

(2018) Christopher L. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis

(2017) Britt J Andersen et al.   JOURNAL OF INFECTIOUS DISEASES

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa

(2017) Peter U. Fischer et al.   PLoS Neglected Tropical Diseases

Measurement of Circulating Filarial Antigen Levels in Human Blood with a Point-of-Care Test Strip and a Portable Spectrodensitometer

(2016) Cédric B. Chesnais et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis

(2015) Edward K. Thomsen et al.   CLINICAL INFECTIOUS DISEASES

Diagnostic Tools for Onchocerciasis Elimination Programs

(2015) Johnny Vlaminck et al.   TRENDS IN PARASITOLOGY

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

(2009) ET Morgan   CLINICAL PHARMACOLOGY & THERAPEUTICS